Advertisement

healthHealth and Medicine

Most Clinical Trial Data In China Is Fabricated, Government Report Finds

author

Ben Taub

author

Ben Taub

Freelance Writer

Benjamin holds a Master's degree in anthropology from University College London and has worked in the fields of neuroscience research and mental health treatment.

Freelance Writer

clockPublished

Many Chinese drug companies are comitting data fraud. motorolka/Shutterstock

Pharmaceutical companies in China are making up the results of their clinical trials in order to get approval to mass produce drugs, according to a report conducted by the country’s State Food and Drug Administration (SFDA). Staggeringly, the government-run investigation found that up to 80 percent of all data published by Chinese drug manufacturers may have been falsified.

According to Chinese newspaper Economic Information Daily, the report looked at the results of 1,622 clinical trials of drugs awaiting approval, and found that many of the findings were either unverifiable, incomplete, or unable to meet the necessary standard for analysis. The SFDA has said that strong economic competition and financial pressures are probably the main motivation for this fraudulent practice, as drug companies are often desperate to get the green light to put their products on the market.

Advertisement

Yet this highly immoral behavior can have potentially disastrous consequences for those who end up using these drugs. For instance, the report found that many companies were deliberately underreporting harmful side effects experienced by participants in their trials, in the hope of gaining the necessary health and safety approval. The SFDA ultimately condemns this practice as a “breach of duty by supervision departments and malpractice by pharmaceutical companies, intermediary agents and medical staff.”

Chinese healthcare professional Luo Liang told Radio Free Asia that the pharmaceutical industry in China is lagging behind that of the US and Europe, meaning companies often resort to foul play in order to win the right to market their second-rate drugs. “There are no new drugs in development in the same way that there are overseas,” he said, adding that Chinese companies regularly manufacture products using formulas that were once under patent but have since expired.


ARTICLE POSTED IN

healthHealth and Medicine
  • tag
  • big pharma,

  • drugs,

  • Pharmaceuticals,

  • side effects,

  • clinical trial,

  • data fraud

FOLLOW ONNEWSGoogele News